| Stomach-Cancer Rate Puzzles Scientists Scientists are puzzling over an unexplained increase in stomach cancer in young white adults, even as a new study shows that rates in all other American adults have declined. online.wsj.com |
Chronic-Fatigue Link to Virus Disputed Two groups of researchers studying a potential link between chronic-fatigue syndrome and a virus called XMRV have reached contradictory conclusions, according to people familiar with the findings. online.wsj.com |
Mannkind Tries Again With Inhaled Insulin The Burrill Report submits: By Michael Fitzhugh Mannkind (MNKD) says it has resubmitted a once-rejected new drug application to the U.S. Food and Drug Administration for its inhaled insulin-and-inhaler combination, Afrezza, securing a promise of agency action on the drug by the end of 2010.Complete Story » seekingalpha.com |
Is Celldex Therapeutics on the Rebound? VFC submits: Barely a week after news broke that Pfizer (PFE) had kicked Celldex Therapeutics (CLDX) to the curb sending the stock price into a steep and rapid decline, CLDX is already on the rebound with a more than twelve percent jump on Monday. There has been no news release that would justify the quick reversal, although a round of insider buying just days after the Pfizer news may have provided a boost in confidence for investors who were shaken and stirred by the bad news. That said, the purchases were for 3,000 shares (by Director Harry Penner) and 2,000 shares (by Officer Avery Catling), by no means convincing purchases. Complete Story » seekingalpha.com |
Healthcare Headlines: Santarus Rallies, Amgen Announces Results M.E. Garza submits: Below is a look at some of the headlines for companies that made news in the healthcare sector on October 5, 2010. Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN (recombinant human C1 inhibitor, or rhC1INH), in the October issue of the peer reviewed Journal of Allergy and Clinical Immunology (JACI).Complete Story » seekingalpha.com |